SEARCH

SEARCH BY CITATION

References

  • 1
    Lok AS, Heathcote EJ, Hoofnagle JH. Management of Hepatitis B 2000, Summary of a Workshop. Gastroenterology 2001; 120:18281853.MEDLINE
  • 2
    Gross PA, Barrett TL, Dellinger EP, Krause PJ, Martone WJ, McGowan JE Jr., Sweet RL, et al. Infectious Diseases Society of America quality standards for infectious diseases: purpose of quality standards for infectious diseases. Clin Infect Dis 1994; 18:421.MEDLINE
  • 3
    Lee W. Hepatitis B virus infection. N Engl J Med 1997; 337:17331745.MEDLINE
  • 4
    McQuillan GM, Townsend TR, Fields HA, Carrol M, Leahy M, Polk BF. Seroepidemiology of hepatitis B virus infection in the United States. Am J Med 1989; 87(Suppl 3A):5S10S.MEDLINE
  • 5
    CDC. Hepatitis B virus: a comprehensive strategy for limiting transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991; 40:RR-131-25.
  • 6
    Beasley RP. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 1988; 61:19421956.MEDLINE
  • 7
    McMahon BJ. Hepatocellular carcinoma and viral hepatitis. In: WilsonRA, ed. Viral Hepatitis. New York: Marcel Dekker 1997;315330.
  • 8
    Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64:5168.MEDLINE
  • 9
    Ganem D, Schneider RJ. Hepadnaviridae and their replication. In: KnipeDM, HowleyPM, ChanockRM, MonathTP, RoizmanB, StrausSE, eds. Fields Virology. 4th ed. Philadelphia: Lippincott-Raven, 2001:27032737.
  • 10
    Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 1997; 233:374381.MEDLINE
  • 11
    Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996; 70:58455851.MEDLINE
  • 12
    Locarnini S, Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. J Hepatol 1999; 30:536550.MEDLINE
  • 13
    Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990; 8(Suppl):S18S20.MEDLINE
  • 14
    Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine 1999; 17:17301733.MEDLINE
  • 15
    Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991; 11:8492.MEDLINE
  • 16
    CDC. Recommendations for protection against viral hepatitis. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1985; 34:313335.
  • 17
    CDC. Prevention of perinatal transmission of hepatitis B virus: prenatal screening of all pregnant women for hepatitis B surface antigen. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1988; 37:341346.
  • 18
    Scharschmidt BF, Held MJ, Hollander HH, Read AE, Lavine JE, Veereman G, McGuire RF, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992; 117:837838.MEDLINE
  • 19
    Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Barrio E. Prevalence, patterns and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. Am J Gastroenterol 2000; 95:13161322.MEDLINE
    Direct Link:
  • 20
    Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week [letter]. Lancet 1981; 1:550551.MEDLINE
  • 21
    Petersen NJ, Barrett DH, Bond WW, Berquist KR, Favero MS, Bender TR, Maynard JE. Hepatitis B surface antigen in saliva, impetiginous lesions, and the environment in two remote Alaskan villages. Applied Environ Microbiol 1976; 32:572574.
  • 22
    Beasley RP, Hwang LY, Lee GCY, Lin CC, Roan CH, Huang FY, Chen CL. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 1:10991102.
  • 23
    Beasley RP, Hwang LY, Lin CC, Leu ML, Stevens CE, Szmuness W, Chen KP. Incidence of hepatitis B virus in preschool children in Taiwan. J Infect Dis 1982; 146:198204.MEDLINE
  • 24
    Corsaget P, Yvonnet B, Chotard J, Vincelot P, Sarr M, Diouf C, Chiron JP, et al. Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal). J Med Virol 1987; 22:15.MEDLINE
  • 25
    McMahon BJ, Alward WLM, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151:599603.MEDLINE
  • 26
    Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92:18441850.MEDLINE
  • 27
    Horvath J, Raffanti SP. Clinical aspects of the interactions between human immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 1994; 18:339347.MEDLINE
  • 28
    Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989; 160:577582.MEDLINE
  • 29
    Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94:744748.MEDLINE
  • 30
    Viola LA, Harrison IG, Coleman JC, Paradinal FJ, Fluker JL, Evans BA, Murray-Lyon IM. Natural history of liver disease in chronic hepatitis B surface antigen carriers: survey of 100 patients from Great Britain. Lancet 1981; 2:11561159.MEDLINE
  • 31
    Liaw YF, Chu CM, Su IJ, Huang MJ, Lin, DY, Chang-Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84:216219.MEDLINE
  • 32
    Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, Guido M, Alberti A, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6:167172.MEDLINE
  • 33
    Lok ASF, Lai CL, Wu PC, Leung EKY, Lam TS. Spontaneous hepatitis e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92:18391843.MEDLINE
  • 34
    Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988; 8:11301133.MEDLINE
  • 35
    Chang MH, Hsu HY, Hsu HC, Ni YH, Chen JS, Chen DS. The significance of spontaneous hepatitis e antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis e antigen before 3 years of age. Hepatology 1995 22;13871392.
  • 36
    Lee PI, Chang MH, Lee CY, Hsu HY, Chen JS, Chen PJ, Chen DS. Changes in serum hepatitis B DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children. Hepatology 1990; 12:657660.MEDLINE
  • 37
    Lok ASK, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B (HBV) virus infection: Incidence, predisposing factors and etiology. J Hepatol 1990; 10:2934.MEDLINE
  • 38
    Dusheiko GM, Brink BA, Conradie JD, Marimuthu T, Sher R. Regional prevalence of hepatitis B, Delta, and human immunodeficiency virus infection in Southern Africa: a large population survey. Am J Epidemiol 1989; 129:138145.MEDLINE
  • 39
    Bortolotti F, Cadrobbi P, Crivellaro C, Guido M, Rugge M, Noventa F, Calzia R, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B infection in childhood. Gastroenterology 1990; 99:805810.MEDLINE
  • 40
    Moreno MR, Otero M, Millan A, Castillo I, Cabrerizo M, Jimenez FJ, Oliva H, et al. Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Hepatology 1999; 29:572575.MEDLINE
  • 41
    Stroffolini T, Mele A, Tosti ME, Gallo G, Balocchini E, Ragni P, Santonastasi F, et al. The impact of hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J Hepatol 2000; 33:980985.MEDLINE
  • 42
    de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, Rumi NG, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118:191194.MEDLINE
  • 43
    McMahon BJ, Holck P, Bulkow L, Snowball MM. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Int Med 2001; 135:759768.
  • 44
    Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999; 29:13061310.MEDLINE
  • 45
    Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of symptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology 1987; 7:302306.MEDLINE
  • 46
    Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984; 86:230235.MEDLINE
  • 47
    Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology 1987; 7:2023.MEDLINE
  • 48
    Fattovich G, Brollo L, Alberti A, Pontisso P, Giustina G, Realdi G. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology 1988; 8:16511654.MEDLINE
  • 49
    Chan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31:763768.MEDLINE
  • 50
    Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge, E, Capalbo M, David E, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10:198202.MEDLINE
  • 51
    Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus - large-scale analysis using a new genotyping method. J Infect Dis 1997; 175:12851293.MEDLINE
  • 52
    Laras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepatitis 1998; 5:241248.
  • 53
    Naoumov NV, Schneider R, Grotzinger T, Jung MC, Miska S, Pape GR, Will H. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992; 102:538543.MEDLINE
  • 54
    Rodriguez-Frias F, Buti M, Jardi R, Cotrina M, Viladomiu L, Esteban R, Guardia J. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995; 22:16411647.MEDLINE
  • 55
    Tu H, Xiong SD, Trepo C, Wen YM. Frequency of hepatitis B virus e-minus mutants varies among patients from different areas of China. J Med Virol 1997; 51:8589.MEDLINE
  • 56
    Shindo M, Hamada K, Koya S, Sokawa Y, Okuno T. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Am J Gastroenterol 1999; 94:237245.
    Direct Link:
  • 57
    Zarski JP, Marcellin P, Cohard M, Lutz JM, Bouche C, Rais A. Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. French Multicentre Group. J Hepatol 1994; 20:636640.MEDLINE
  • 58
    Gray AH, Fang JW, Davis GL, Mizokami M, Wu PC, Williams R, Schuster SM, et al. Variations of hepatitis B virus core gene sequence in Western patients with chronic hepatitis B virus infection. J Viral Hepatitis 1997; 4:371378.
  • 59
    Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, Maisonnas M, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000; 33:430439.MEDLINE
  • 60
    Hadziyannis S. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis Rev 1995; 1:736.
  • 61
    Di Marco V, Camma C, Vaccaro A, Giunta M, Martorana G, Fuschi P, Almasio P, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30:257264.MEDLINE
  • 62
    Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A, Serra A, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991; 88:41864190.MEDLINE
  • 63
    Chu CM, Yeh CT, Chiu CT, Sheen IS, Liaw YF. Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic. J Clin Microbiol 1996; 34:18151818.MEDLINE
  • 64
    Kramvis A, Kew MC, Bukofzer S. Hepatitis B virus precore mutants in serum and liver of Southern African blacks with hepatocellular carcinoma. J Hepatol 1998; 28:132141.
  • 65
    Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91:40774081.MEDLINE
  • 66
    Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2:588591.MEDLINE
  • 67
    Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68:81028110.MEDLINE
  • 68
    Magnius LO, Norder H. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Intervirology 1995; 38:2434.MEDLINE
  • 69
    Adachi J, Kaneko S, Matsushita E, Inagaki Y, Unoura M, Kobayashi K. Clearance of HBsAg in seven patients with chronic hepatitis. Hepatology 1992; 16:13341337.MEDLINE
  • 70
    Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13:627631.MEDLINE
  • 71
    Gandhi, MJ, Yang GG, McMahon B, Vyas G. Hepatitis B virions isolated with antibodies to the pre-S1 domain reveal occult viremia in surface antigen negative/antibody-positive carriers by polymerase chain reaction. Transfusion 2000: 40:910916.MEDLINE
  • 72
    Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, Chen CJ, Liaw YF. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145:10391047.MEDLINE
  • 73
    Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8:493496.MEDLINE
  • 74
    Fatttovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, Realdi G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32:294298.MEDLINE
  • 75
    Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, Christensen E, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994; 21:656666.MEDLINE
  • 76
    De Jongh FE, Janssen HLA, De Man FA, Hop WCJ, Schalm SW, Van Blankenstein MV. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103:16301635.MEDLINE
  • 77
    Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, Christensen E, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21:7782.MEDLINE
  • 78
    Niederau C, Heintges T, Lange S, Goldman G, Niederau CM, Mohr L, Hausssinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334:14221427.MEDLINE
  • 79
    Fattovich G, Giustina G, Realdi G, Corroacher R, Schalm SW, and the European Concerted Action of Viral Hepatitis (EUROHEP). Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997; 26:13381342.MEDLINE
  • 80
    Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29:971975.MEDLINE
  • 81
    Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113:16601667.MEDLINE
  • 82
    Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9:235241.MEDLINE
  • 83
    Chung HT, Lai CL, Lok AS. Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology 1995; 22:2529.MEDLINE
  • 84
    Huo TI, Wu JC, Lee PC, Chau GY, Lui WY, Tsai SH, Ting LT, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998; 28:231236.MEDLINE
  • 85
    Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeax D, and the Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. Hepatology 1997; 26:485490.MEDLINE
  • 86
    Housset C, Pol S, Carnot F, Dubois F, Nalpas B, Housset B, Berthelot P, et al. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus. Hepatology 1992; 15:578592.MEDLINE
  • 87
    Hadziyannis SJ. Hepatitis D. Clin Liver Dis 1999; 3:309325.
  • 88
    Hadler SC, Alcala de Monzon M, Rivero D, Perez M, Bracho A, Fields H. Epidemiology and long-term consequences of hepatitis Delta virus infection in the Yucpa Indians of Venezuela. Am J Epidemiol 1992; 136:15071516.MEDLINE
  • 89
    Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, Lorello S, Sagnelli E, et al. Chronic hepatitis D: a vanishing disease? An Italian multinational study. Hepatology 2000; 32:824827.MEDLINE
  • 90
    Caredda F, Rossi E, d'Arminio Monteforte A, Zampini L, Re T, Meroni B, Moroni M. Hepatitis B virus-associated coinfection and superinfection with delta agent: Indistinguishable disease with different outcome. J Infect Dis 1985; 151:925928.MEDLINE
  • 91
    Fattovich G, Boscaro S, Noventa F, Pornaro E, Stenico D, Alberti A, Ruol A, et al. Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis 1987; 155:931935.MEDLINE
  • 92
    Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW, and the European Concerted Action on Viral Hepatitis (Eurohep). Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000; 46:420426.MEDLINE
  • 93
    Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45:130.
  • 94
    Gerlich WH, Thomssen R. Quantitative assays for hepatitis B virus DNA: standardization and quality control. Viral Hepatitis Reviews 1995; 1:5357.
  • 95
    Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method. J Clin Microbiol 1997; 35:187192.MEDLINE
  • 96
    Pawlotsky JM, Bastie A, Hezode C, Lonjon I, Darthuy F, Remire J, Dhumeaux D. Routine detection and quantification of hepatitis B virus DNA in clinical laboratories: performance of three commercial assays. J Virol Methods 2000; 85:1121.MEDLINE
  • 97
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:15131520.MEDLINE
  • 98
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431435.MEDLINE
  • 99
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696699.MEDLINE
  • 100
    The French Metavir Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20:1520.MEDLINE
  • 101
    Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, Robinson WS, et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984; 101:613616.MEDLINE
  • 102
    Villa E, Rubbiani L, Barchi T, Ferretti I, Grisendi A, De Palma M, Bellentani S, et al. Susceptiblility of chronic symptomless HBsAg carriers to ethanol-induced hepatic damage. Lancet 1982; 2:12431245.MEDLINE
  • 103
    Kim YI, Heathcote J, Wanless IR. The hepatitis B carrier state—a follow-up study of 100 consecutive cases. Clin Invest Med 1987; 10:383387.MEDLINE
  • 104
    Chevillotte G, Durbec JP, Gerolami A, Berthezene P, Bidart JM, Camatte R. Interaction between hepatitis B virus and alcohol consumption in liver cirrhosis: an epidemiologic study. Gastroenterology 1983; 85:141145.MEDLINE
  • 105
    Imanishi T, Morikawa S, Ohmagari K, Kurihara S, Nishihata S, Kamiya T, Hayashida K, et al. The effect of habitual alcohol drinking on the development of type B chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Jpn J Gastroenterol 1988; 85:692698.
  • 106
    Chung HT, Lai CL, Wu PC, Lok ASF. Synergism of chronic alcoholism and hepatitis B infection in liver disease. J Gastroenterol Hepatol 1989; 4:1116.MEDLINE
  • 107
    Lok ASF, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programs. Hepatology 1988; 8:766770.MEDLINE
  • 108
    McMahon BJ, Parkinson AJ. Clinical significance and management when antibody to hepatitis B core antigen is the sole marker for HBV infection. Viral Hepatitis Rev 2000; 6:229236.
  • 109
    Wong VC, Ip HM, Reesink HW, Lelie PN. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Lancet 1984; 1:921926.MEDLINE
  • 110
    Burk RD, Hwang LY, Ho GYF, Shafritz D, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994; 170:14181423.MEDLINE
  • 111
    Harpaz R, Von Seidlein L, Averhoff FM, Tormey MP, Sinha SD, Kotsopoulou K, Lambert SB, et al. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med 1996; 334:549554.MEDLINE
  • 112
    Gerberding JL. The infected health care provider. N Engl J Med 1996; 334:594595.MEDLINE
  • 113
    CDC. Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-prone invasive procedures. MMWR 1991; 40:RR-8:1-7.
  • 114
    Heyward WL, Bender TR, Lanier AP, Francis DP, McMahon BJ, Maynard JE. Serologic markers of hepatitis B virus and alpha-fetoprotein levels preceding primary hepatocellular carcinoma in Alaskan Eskimos. Lancet 1982; 2:889891.MEDLINE
  • 115
    Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: Influence of therapy and possible value in early detection. J Nat Cancer Inst 1980; 64:13291332.
  • 116
    Kaneko S, Unoura M, Kobayashi K. Early detection of hepatocellular carcinoma. In: OkudaK and TaborE, eds. Liver Cancer. New York: Churchill Livingstone 1997;393406.
  • 117
    Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, Hsu HC, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89:259266.MEDLINE
  • 118
    Tang ZY, Yang BH, Zhou XD. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol 1995; 10:683690.MEDLINE
  • 119
    McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, Dunaway E, et al. Screening for hepatocellular carcinoma in Alaska Natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32:842846.MEDLINE
  • 120
    Lee CS, Sheu JC, Wang M, Hsu HC. Long-term outcome after surgery for asymptomatic small hepatocellular carcinoma. Br J Surg 1996; 83:330333.MEDLINE
  • 121
    Mima S, Sekiya C, Kanagawa H, Kohyama H, Gotoh K, Mizuo H, Ijiri M, et al. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol 1994; 9:361655.MEDLINE
  • 122
    Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22:432437.MEDLINE
  • 123
    Sheu JC, Sung JL, Chen DS, Lai MY, Wang TH, Yu JY, Yang PM. Early detection of hepatocellular carcinoma by real-time ultrasonography. Cancer 1985; 56:660666.MEDLINE
  • 124
    Dusheiko GM, Hobbs KEF, Dick R, Burroughs AK. Treatment of small hepatocellular carcinomas. Lancet 1992; 340:285288.MEDLINE
  • 125
    Mor E, Kaspa RT, Sheiner P, Schwartz M. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998; 129:643653.MEDLINE
  • 126
    Liu CL, Fan ST. Nonresectional therapies for hepatocellular carcinoma. Am J Surg 1997; 173:358365.MEDLINE
  • 127
    Murakami R, Yoshimatsu S, Yamashita Y, Matsukawa T, Takahashi M, Sagara K. Treatment of hepatocellular carcinoma: value of percutaneous microwave coagulation. Am J Radiol 1995; 164:11591164.
  • 128
    Matsuzaki Y, Osuga T, Saito Y, Chuganji Y, Tanaka N, Shoda J, Tsuji H, et al. A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology 1994; 106:10321041.MEDLINE
  • 129
    Gazelle GS, Goldberg SN, Solbiati L, Livraghi T. Tumor ablation with radio-frequency energy. Radiology 2000; 217:633646.MEDLINE
  • 130
    Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996; 78:977985.MEDLINE
  • 131
    Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, Kobayashi K. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12:680687.MEDLINE
  • 132
    Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G, Virdone R, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8 year prospective study by ultrasound and alpha-fetoprotein. J Hepatol 1994; 21:10291034.MEDLINE
  • 133
    Colombo M, de Franchis R, Del Ninno, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325:675680.MEDLINE
  • 134
    Tanaka S, Kitamura T, Nakanishi K, Okuda S, Yamazaki H, Hiyama T, Fujimoto I. Effectiveness of periodic checkup by ultrasonography for the early diagnosis of hepatocellular carcinoma. Cancer 1990; 66:22102214.MEDLINE
  • 135
    Fujiyama S, Izuno K, Gohshi K, Shibata J, Sato T. Clinical usefulness of Des-γ-carboxy prothombin in early diagnosis of hepatocellular carcinoma. Dig Dis Science 1991; 36:17871792.
  • 136
    Tanabe Y, Ohnishi K, Nomura F, Iida S. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma. Am J Gastroenterol 1988; 83:13861389.MEDLINE
  • 137
    Tsai Sl, Huang GT, Yang PM, Sheu JC, Sung JL, Chen DS. Plasma Des-γ-carboxy prothombin in early stage of hepatocellular carcinoma. Hepatology 1990; 11:481487.MEDLINE
  • 138
    Xu K, Meng XY, Wu JW, Shen B, Shi YC, Wei Q. Diagnostic value of serum γ-glutamyl transferase isoenzyme for hepatocellular carcinoma: a 10-year study. Am J Gastroenterology 1992; 87:991995.
  • 139
    Takahashi H, Saibara T, Iwamura I, Tomita A, Maeda T, Onishi S, Yamamoto Y, et al. Serum α-L- fucosidase activity and tumor size in hepatocellular carcinoma. Hepatology 1994; 19:14141417.MEDLINE
  • 140
    Giardina MG, Matarazzo M, Morante R, Lucariello A, Varriale A, Guardasole V, De Marco G. Serum α-L-fucosidase activity and early detection of hepatocellular carcinoma. Cancer 1998; 83:24682474.MEDLINE
  • 141
    Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining Des-γ-carboxy prothombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998; 82:16431648.MEDLINE
  • 142
    Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi, K. Serum Des-gamma-carboxy prothombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999; 94:650654.MEDLINE
    Direct Link:
  • 143
    Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CGC, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31:330335.MEDLINE
  • 144
    Solmi L, Primerano AMM, Gandolfi L. Ultrasound follow-up of patients at risk for hepatocellular carcinoma: Results of a prospective study on 360 cases. Am J Gastroenterol 1996; 91:11891194.MEDLINE
  • 145
    Kang JY, Lee TP, Yap I, Lun KC. Analysis of cost-effectiveness of different strategies for hepatocellular carcinoma screening in hepatitis B virus carriers. J Gastroenterol Hepatol 1992; 7:463468.MEDLINE
  • 146
    Mark DB, Hiatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332:14181424.MEDLINE
  • 147
    Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1993; 119:312323.MEDLINE
  • 148
    Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? Hepatology 1989; 10:761763.MEDLINE
  • 149
    Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC, Jr., Lindsay K, Payne J, Dienstag JL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323:295301.MEDLINE
  • 150
    Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, Ma OC, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102:20912097.MEDLINE
  • 151
    Lai CL, Lok AS, Lin HJ, Wu PC, Yeoh EK, Yeung CY. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet 1987; 2:877880.MEDLINE
  • 152
    Lai CL, Lin HJ, Lau JN, Lok AS, Wu PC, Chung HT, Wong LK, et al. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991; 78:155163.MEDLINE
  • 153
    Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2:298302.MEDLINE
  • 154
    Gregorio GV, Jara P, Hierro L, Diaz C, de la Vega A, Vegnente A, Iorio R, et al. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial. Hepatology 1996; 23:700707.MEDLINE
  • 155
    Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, Rosenthal P, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998; 114:988995.MEDLINE
  • 156
    Jara P, Bortolotti F. Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr 1999; 29:163170.MEDLINE
  • 157
    Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996; 23:131137.MEDLINE
  • 158
    Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Morabito A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26:16211625.MEDLINE
  • 159
    Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, Giustina G, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992; 15:584589.MEDLINE
  • 160
    Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 1990; 11(Suppl 1):S133S136.MEDLINE
  • 161
    Pastore G, Santantonio T, Milella M, Monno L, Mariano N, Moschetta R, Pollice L. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992; 14:221225.MEDLINE
  • 162
    Oliveri F, Santantonio T, Bellati G, Colombatto P, Mels GC, Carriero L, Dastoli G, et al. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol 1999; 94:13661372.MEDLINE
  • 163
    Papatheodoridis GV, Manesis E, Hadziyannis SJ. Long-term follow up after initial response to interferon therapy in patients with HBeAg negative chronic hepatitis B (abstract). Hepatology 2000; 32:378A.
  • 164
    Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alfa treated and untreated patients with HBeAg negative chronic hepatitis B. J Hepatol 2001; 34:306313.MEDLINE
  • 165
    Carreno V, Marcellin P, Hadziyannis S, Salmeron J, Diago M, Kitis GE, Vafiadis I, et al. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30:277282.MEDLINE
  • 166
    Perrillo R, Tamburro C, Regenstein F, Balart L, Bodenheimer H, Silva M, Schiff E, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109:908916.MEDLINE
  • 167
    Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104:11161121.MEDLINE
  • 168
    Saracco G, Mazzella G, Rosina F, Cancellieri C, Lattore V, Raise E, Rocca G, et al. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology 1989; 10:336341.MEDLINE
  • 169
    Scully LJ, Shein R, Karayiannis P, McDonald JA, Thomas HC. Lymphoblastoid interferon therapy of chronic HBV infection. A comparison of 12 vs. 24 weeks of thrice weekly treatment. J Hepatol 1987; 5:5158.MEDLINE
  • 170
    Janssen HL, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen H, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30:238243.MEDLINE
  • 171
    Cohard M, Poynard T, Mathurin P, Zarski JP. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect meta-analysis. Hepatology 1994; 20:13901398.MEDLINE
  • 172
    Krogsgaard K, Marcellin P, Trepo C, Berthelot P, Sanchez-Tapias JM, Bassendine M, Tran A, et al. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group. J Hepatol 1996; 25:803813.MEDLINE
  • 173
    Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122:664675.MEDLINE
  • 174
    Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105:18331838.MEDLINE
  • 175
    Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114:629634.MEDLINE
  • 176
    Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat 1998; 5:389397.MEDLINE
  • 177
    Carreno V, Castillo I, Molina J, Porres JC, Bartolome J. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992; 15:102106.MEDLINE
  • 178
    Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993; 18:13131318.MEDLINE
  • 179
    Bortolotti F, Jara P, Barbera C, Gregorio GV, Vegnente A, Zancan L, Hierro L, et al. Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000; 46:715718.MEDLINE
  • 180
    Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, et al. Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. N Engl J Med 1999; 341:12561263.MEDLINE
  • 181
    Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:6168.MEDLINE
  • 182
    Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46:562568.MEDLINE
  • 183
    Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119:172180.MEDLINE
  • 184
    Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Wu PC, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:15271532.MEDLINE
  • 185
    Chang TT, Lai CL, Liaw YF, Guan R, Lim SG, Lee CM, Ng KY, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years (abstract). Antiviral Therapy 2000; 5(Suppl 1):44.
  • 186
    Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology 1999; 30:770774.MEDLINE
  • 187
    Perrillo RP, Schalm SW, Schiff ER, Brown NA, Woessner MA, Sullivan M. Predictors of HBsAg seroconversion in chronic hepatitis B patients treated with lamivudine (abstract). Hepatology 1999; 30:317A.
  • 187a
    Sokal EM, Kelly D, Mizerski J, Badia I, Areias J, Schwarz K, Little N, Bell S, Greensmith MJ, Jonas M. An international double-blind placebo-controlled trial of lamivudine in 286 children with chronic hepatitis B (CHB). J Hepatol 2001; 34(Suppl 1):23A.
  • 188
    Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, et al. Efficacy of lamivudine in patients with hepatitis B e antigen- negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group. Hepatology 1999; 29:889896.MEDLINE
  • 189
    Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32:300306.MEDLINE
  • 190
    Lok ASF, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32:11451153.MEDLINE
  • 191
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32:847851.MEDLINE
  • 192
    Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32:828834.MEDLINE
  • 193
    Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000; 61:398400.MEDLINE
  • 194
    Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Gray DF, Barber J, et al. Post lamivudine treatment follow-up of patients with HBeAg negative chronic hepatitis B (abstract). J Hepatol 1999; 30(Suppl 1):117.
  • 195
    Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, Schalm S, et al. A placebo controlled study of lamivudine and interferon alpha 2b in patients with chronic hepatitis B who previously failed interferon therapy (abstract). Hepatology 1998; 28:388A.
  • 196
    Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, Martin P, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33:424432.MEDLINE
  • 197
    Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, Leduc R, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207210.MEDLINE
  • 198
    Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33:301307.MEDLINE
  • 199
    Fontana RJ, Perrillo R, Hann HWL, Wright T, Rakela J, Bacon BR, Anschuetz G, et al. Determinants of survival in 133 patients with decompensated chronic hepatitis B treated with lamivudine (abstract). Hepatology 2000; 32:221A.
  • 200
    Schiff E, Cianciara J, Karayalcin S, Kowdley K, Woesner M, McMullen S, Pearce M, et al. Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B (abstract). J Hepatol 2000; 32(Suppl 2):99.
  • 201
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32:803806.MEDLINE
  • 202
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27:16701677.MEDLINE
  • 203
    Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751757.MEDLINE
  • 204
    Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30:567572.MEDLINE
  • 205
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:2022.MEDLINE
  • 206
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714717.MEDLINE
  • 207
    Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628633.MEDLINE
  • 208
    Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 1999; 29:939945.MEDLINE
  • 209
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:16571661.MEDLINE
  • 210
    Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25:241244.MEDLINE
  • 211
    Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32:635639.MEDLINE
  • 212
    de Man RA, Marcellin P, Habal F, Desmond P, Wright T, Rose T, Jurewicz R, et al. A randomized, placebo-controlled study to evaluate the efficacy of 12- month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000; 32:413417.MEDLINE
  • 213
    Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26:11481153.MEDLINE
  • 214
    Heathcote EJ, Jeffers L, Wright T, Sherman M, Perrillo R, Sacks S, Carithers R, et al. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo controlled phase II studies (abstract). Hepatology 1998; 28:317A.
  • 215
    Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:16691673.MEDLINE
  • 216
    Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129134.MEDLINE
  • 217
    Gish RG, Leung NWY, Wright TL, Trinh H, Robertson AT, Harris JJ, Delehanty JT, et al. Anti-hepatitis B virus (HBV) activity and pharmacokinetics of FTC in a 2 month trial in HBV infected patients (abstract). Gastroenterology 1999; 116:A1216.
  • 218
    de Man R, Wolters L, Nevens F, Chua D, Sherman M, Lai CL, Thomas N, et al. A study of oral entecavir given for 28 days in both treatment-naïve and pre-treated subjects with chronic hepatitis (abstract). Hepatology 2000; 32:376A.
  • 219
    Ono-Nita SK, Kato N, Shiratori Y, Yoshida H, Kato J, Goto T, Schinazi RF, et al. Influence of B domain mutation (L528M) of the hepatitis B virus polymerase on replication ability and resistance to nucleoside analogues (abstract). Hepatology 2000; 32:393A.
  • 220
    Andreone P, Cursaro C, Gramenzi A, Zavagliz C, Rezakovic I, Altomare E, Severini R, et al. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody– and hepatitis B virus DNA–positive chronic hepatitis B. Hepatology 1996; 24:774777.MEDLINE
  • 221
    Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998; 27:13831387.MEDLINE
  • 222
    Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman HD, Peleman RR, Silva M, et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat 1999; 6:397403.MEDLINE
  • 223
    Zavaglia C, Severini R, Tinelli C, Franzone JS, Airoldi A, Tempini S, Bettale G, et al. A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig Dis Sci 2000; 45:690696.MEDLINE
  • 224
    Lau GK, Tsiang M, Hou J, Yuen S, Carman WF, Zhang L, Gibbs CS, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 2000; 32:394399.MEDLINE
  • 225
    Rosina F, Pintus C, Meschievitz C, Rizzetto M. A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: a multicenter Italian study. Hepatology 1991; 13:10521056.MEDLINE
  • 226
    Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, Gibo Y, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330:8894.MEDLINE
  • 227
    Farci P, Chessa L, Peddis G, Strazzera R, Pascariello E, Scioscia R, Lai ME, et al. Influence of alfa interferon on the natural history of chronic hepatitis D: dissociation of histologic and virologic response (abstract). Hepatology 2000; 32:222A.
  • 228
    Lau DT, Doo E, Park Y, Kleiner DE, Schmid P, Kuhns MC, Hoofnagle JH. Lamivudine for chronic delta hepatitis. Hepatology 1999; 30:546549.MEDLINE